Imaging Technology

Radiolabeled Agent Helps Identify Prostate Cancer With Greater Accuracy

Published in Cancer Weekly, July 31st, 2001

A new study by doctors at New York University (NYU) School of Medicine found that it is possible to identify recurrent prostate cancer with greater precision by using the radiolabeled imaging agent ProstaScint^R (Capromab Pendetide) in combination with other diagnostic imaging techniques.

The results of this and two related studies were announced June 26, 2001, at the 48th Society of Nuclear Medicine annual meeting in Toronto, Canada. The study by researchers at NYU found that ProstaScint imaging, when combined or fused with MRI (magnetic resonance imaging) or CT (computed tomography) scans in a digital overlay, offers a more specific evaluation of prostate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry